Clinical trials: Malignant Breast Tumours
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Breast Carcinoma, Cervical Carcinoma
Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization
This pilot trial study uses a structural support program for adoption of cancer screening interventions at a rural community-based organization.
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT04208724
- Testing
- Training, Cancer Screening intervention, Survey Administration
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, BIRADS 3
DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer
A type of magnetic resonance imaging called diffusion weighted imaging (DWI) will be tested to define cancerous from non-cancerous lesions in the breast.
- Conditions
- Breast Cancer, BIRADS 3, BIRADS 4, BIRADS 5
- Trial name
- ACRIN6702 (NCT02022579)
- Testing
- DCE-MRI and DWI
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- American College of Radiology Imaging Network
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Benign Breast Neoplasm, Breast Carcinoma
MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer
This trial studies how well an imaging technique called magnetic resonance (MR) spectroscopic imaging works in identifying breast cancer in women with benign or suspicious areas in the breast.
- Conditions
- Benign Breast Neoplasm, Breast Carcinoma, Malignant Breast Neoplasm
- Trial name
- NCT06090630
- Testing
- Diffusion Weighted Imaging, Magnetic Resonance Spectroscopic Imaging
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Neoplasm of Breast.
Discordant HER2/Neu Status of Breast Cancer.
The purpose of this study is to determine discordant HER2/neu status of primary breast tumor and metastatic breast cancer cells at regional lymph nodes in node positive breast cancer patients.
- Trial name
- NCT01935739
- Where
- Thailand
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute, Thailand
Breast, Neoplasm Malignant
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
This is a multicentre real-world experience aimed at verifying the outcome of palbociclib plus ET in an unselected population of MBC patients.
- Conditions
- Breast, Neoplasm Malignant, Female
- Trial name
- NCT04524728
- Testing
- Palbociclib, Letrozole 2.5mg, Fulvestrant
- Where
- Italy
- Volunteers
- 191 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Lung Cancer, Breast Cancer
Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion
This is a prospective, open-label , multicenter randomized controlled trial, with 248 cases in 50 centers planned for a period of 2 years.
- Conditions
- Lung Cancer, Breast Cancer, Malignant Pleural Effusion
- Trial name
- NCT04131231
- Testing
- microparticles packaging methotrexate (MPs-MTX), recombinant human interleukin-2(rhIL-2)
- Volunteers
- 248 people
- Sponsor
- Peking Union Medical College
Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma
Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer
This study evaluates how useful and acceptable the components of the "Couples Coping Together Against Cancer", referred to as "The Program", are to the participants with cancer.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma, Lung Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT07664579
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Malignant Neoplasm of Breast, Breast Cancer
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
This study will examine the combination of pembrolizumab and olaparib in three populations. Cohort 1: aBC patients with a germline mutation in BRCA1 or BRCA2, cohort 2: aBC patients with a germline mutation in one of the moderate…
- Trial name
- COMPRENDO (NCT05033756)
- Testing
- Pembrolizumab Injection [Keytruda], Olaparib Oral Tablet [Lynparza]
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Institut fuer Frauengesundheit
Triple Negative Breast Cancer, Uterine Cervical Cancer
Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy
The aim of the study is to evaluate the response to four schemes of treatment with novel diagnostic tools - Immuno-PET and proteomics as well as standard imaging (magnetic resonsonce imaging and computed tomography).
- Conditions
- Triple Negative Breast Cancer, Uterine Cervical Cancer, Uterine Corpus Cancer, Malignant Melanoma
- Trial name
- INTROSPECTION (NCT06976021)
- Testing
- Baseline 89-Zr Pembrolizumab Immuno PET-CT, Proteomic assay, Follow-up 89-Zr Pembrolizumab Immuno PET-CT
- Volunteers
- 60 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Breast Cancer, Persistant Organic Pollutants
Persistant Organics Pollutants in Breast Cancer.
Persistant Organics Pollutants (POP) accumulate in the adipose tissue (AT) and could modulate tumor progression as part of the microenvironment.
- Conditions
- Breast Cancer, Persistant Organic Pollutants, Lymph Node Metastases
- Trial name
- METAPOP (NCT03788187)
- Testing
- Blood test sample, Peritumoral adipose tissue sample
- Volunteers
- 80 people
- Sponsor
- European Georges Pompidou Hospital
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer drug.
- Conditions
- Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer, Small Cell Lung Cancer, Urothelial Cancer
- Trial name
- NCT02661100
- Testing
- Pembrolizumab, CDX-1401, Poly-ICLC
- Sponsor
- Case Comprehensive Cancer Center
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer, Leukemia
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00060255
- Testing
- busulfan, carboplatin, carmustine
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Right or Left Breast Mammary Reconstruction
Psycho-esthetic Impact of Tattoo Technology as Part of Mammary Reconstruction After Surgery Against Breast Cancer
Mammary reconstruction replaces total skin transplant, which may causing patient discomfort. It is a simple, painless and reproductible technology that avoids consequences and complications related to transplant.
- Conditions
- Breast Cancer, Right or Left Breast Mammary Reconstruction, Malignant Neoplasm Reconstruction by Tattoo of Areola of Female Breast
- Trial name
- NCT02464982
- Testing
- Tattoo
- Where
- France
- Volunteers
- 107 people
- Sponsor
- University Hospital, Strasbourg, France